Insite Vision (INSV) 10-Q 12 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	11-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	INSV
Entity Registrant Name	INSITE VISION INC
Entity Central Index Key	802724
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		131,951,033

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$1,050	$1,656	[1]
Accounts receivable	363	349	[1]
Prepaid expenses and other current assets	272	36	[1]
Debt issuance costs, net	895	1,267	[1]
Total current assets	2,580	3,308	[1]
Property and equipment, net	1,518	1,597	[1]
Total assets	4,098	4,905	[1]
Current liabilities:
Accounts payable	539	611	[1]
Accrued liabilities	640	660	[1]
Accrued compensation and related expense	1,691	1,655	[1]
Accrued royalties	900	892	[1]
Accrued interest	241	85	[1]
Lease incentive, current	186	186	[1]
Secured notes payable	5,199	5,199	[1]
Warrant liability	959	1,191	[1]
Total current liabilities	10,355	10,479	[1]
Deferred revenue	1,000	1,000	[1]
Lease incentive	882	928	[1]
Total liabilities	12,237	12,407	[1]
Commitments and contingencies			[1]
Stockholders' deficit:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, none issued and outstanding			[1]
Common stock, $0.01 par value, 240,000,000 shares authorized; 131,951,033 shares issued and outstanding at March 31, 2015 and December 31, 2014	1,320	1,320	[1]
Additional paid-in capital	166,631	166,440	[1]
Accumulated deficit	-176,090	-175,262	[1]
Total stockholders' deficit	-8,139	-7,502	[1]
Total liabilities and stockholders' deficit	$4,098	$4,905	[1]
[1]	Derived from the Company's audited consolidated financial statements as of December 31, 2014.

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, par value	$0.01	$0.01	[1]
Preferred stock, shares authorized	5,000,000	5,000,000	[1]
Preferred stock, shares issued	0	0	[1]
Preferred stock, shares outstanding	0	0	[1]
Common stock, par value	$0.01	$0.01	[1]
Common stock, shares authorized	240,000,000	240,000,000	[1]
Common stock, shares issued	131,951,033	131,951,033	[1]
Common stock, shares outstanding	131,951,033	131,951,033	[1]
[1]	Derived from the Company's audited consolidated financial statements as of December 31, 2014.

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Royalties	$359	$1,146
Licensing fee	3,000
Other revenues	17	7
Total revenues	3,376	1,153
Expenses:
Research and development	2,104	2,547
General and administrative	1,638	1,940
Cost of revenues, principally royalties to third parties	131	138
Total expenses	3,873	4,625
Loss from operations	-497	-3,472
Interest expense and other, net	-563	-1,787
Change in fair value of warrant liability	232	580
Net loss	($828)	($4,679)
Net loss per share:
Loss per share - basic	($0.01)	($0.04)
Loss per share - diluted	($0.01)	($0.04)
Weighted average shares used in per-share calculation:
- Basic	131,951	131,951
- Diluted	131,951	131,951

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015		Mar. 31, 2014
OPERATING ACTIVITIES:
Net loss	($828)		($4,679)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	85		81
Amortization of debt issuance costs	372		103
Amortization of lease incentive	-46		-46
Stock-based compensation	191		252
Change in fair value of warrant liability	-232		-580
Changes in operating assets and liabilities:
Accounts receivable	-14		-120
Other receivables			461
Prepaid expenses and other current assets	-236		-225
Accounts payable	-72		413
Accrued liabilities	-20		-140
Accrued compensation and related expense	36		35
Accrued royalties	8		134
Accrued interest	156		1,665
Net cash used in operating activities	-600		-2,646
INVESTING ACTIVITIES:
Purchase of property and equipment	-6		-252
Decrease in short-term investments			4,000
Net cash provided by (used in) investing activities	-6		3,748
Net increase (decrease) in cash and cash equivalents	-606		1,102
Cash and cash equivalents at beginning of period	1,656	[1]	3,251
Cash and cash equivalents at end of period	1,050		4,353
Supplemental disclosure of cash flow information:
Interest received			1
Interest paid			18
Income taxes paid	$1		$1
[1]	Derived from the Company's audited consolidated financial statements as of December 31, 2014.

Significant_Accounting_Policie

Significant Accounting Policies and Use of Estimates	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies and Use of Estimates	Note 1. Significant Accounting Policies and Use of Estimates
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements include the accounts of InSite Vision Incorporated (“InSite” or the “Company”) and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the preparation of the condensed consolidated financial statements.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial results and financial condition have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for any future period.
	The Company operates in one segment using one measure of profitability to manage its business. All of the Company’s long-lived assets are located in the United States. Revenues are primarily royalties from the North American license (the “Akorn License”) of AzaSite® to Akorn, Inc. (“Akorn”).
	In January 2015, the Company entered into a license agreement with Nicox S.A. (“Nicox”), a France-based publicly traded company, for the development and commercialization of AzaSite (1% azithromycin), AzaSite XtraTM (2% azithromycin) and BromSiteTM (0.075% bromfenac) in Europe, Middle East and Africa (105 total countries). Under the terms of the license, the Company received an upfront payment of $3.0 million and could potentially receive $13.75 million in milestone payments. The Company will also receive tiered, mid-single digit to double-digit royalties on the net sales of these three products.
	Under the license agreement, Nicox can request up to twelve full-time equivalent (“FTE”) employees from the Company to assist with presenting data to regulatory authorities in the European Union, obtaining European Union regulatory approvals and dealing with the approved product manufacturer in the United States. Nicox has agreed to reimburse the Company for the use of its employees. Should the twelve FTE employees be needed for a full year, the reimbursement to the Company would be approximately $3.6 million.
	A joint collaboration and development committee will oversee further product development of the licensed products for the European Union including AzaSite Xtra and any additional indications for BromSite. The Company has the right to utilize the jointly developed data for regulatory approval outside of the Nicox territory including in the United States. Each company will bear 50% of the development cost.
	Historically, the Company has incurred substantial cumulative losses and negative cash flows from operations. Clinical trials and costs to prepare a New Drug Application (“NDA”) for the Company’s product candidates with the U.S. Food and Drug Administration (“FDA”) are very expensive and difficult, in part because they are subject to rigorous regulatory requirements. As of March 31, 2015, the Company’s accumulated deficit was $176.1 million and its cash and cash equivalents were $1.1 million. Further, the Company anticipates that its cash and cash equivalents balance, anticipated cash flows from operations and the net proceeds from existing debt financing arrangements will only be adequate to fund its operations until approximately July 2015. Management is exploring strategic alternatives or the raising of additional financing. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects relating to the recoverability and classification of the recorded asset amounts or amounts and classification of liabilities that might result from the outcome of this uncertainty.
	These unaudited condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
	Use of Estimates
	The preparation of financial statements requires the Company to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
	Warrant Liability
	The Company issued warrants to purchase shares of the Company’s common stock in connection with a private placement equity financing transaction in July 2011 and private placement debt financing transactions in the fourth quarter of 2014. The Company accounted for these warrants as a liability measured at fair value due to a provision included in the warrant agreements that provides the warrant holders with an option to require the Company (or its successor) to purchase their warrants for cash in the event of a “Fundamental Transaction” (as defined in the warrant agreements). The actual amount of cash required if the mandatory purchase option is exercised would be determined using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”) as determined in accordance with the terms of the warrant agreements. The fair value of the warrant liability is estimated using the Black-Scholes Model, which requires inputs such as the remaining term of the warrants, share price volatility and risk-free interest rate. These assumptions are reviewed on a monthly basis and changes in the estimated fair value of the outstanding warrants are recognized each reporting period in the Condensed Consolidated Statements of Operations under “Change in fair value of warrant liability.”
	Fair Value Measurements
	Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
	Level 1:	Quoted prices in active markets for identical assets or liabilities.
	Level 2:	Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3:	Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.
	The Company’s financial instruments consist mainly of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and debt obligations. Accounts receivable and accounts payable are reflected in the accompanying unaudited condensed consolidated financial statements at cost, which approximates fair value due to the short-term nature of these instruments. While the Company believes its valuation methodologies are appropriate and consistent with those of other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
	At March 31, 2015, less than $0.1 million of the Company’s cash and cash equivalents consisted of Level 1 U.S. Treasury-backed government securities or money market funds that are measured at fair value on a recurring basis.
	As discussed above, the fair value of the warrant liability, determined using Level 3 criteria, was initially recorded on the grant date and remeasured at March 31, 2015 and December 31, 2014 using the Black-Scholes Model, which requires inputs such as the remaining term of the warrants, share price volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. A significant increase (decrease) of any of the subjective variables would result in a correlated increase (decrease) in the warrant liability and an inverse effect on net income (loss).
	The fair value of the warrant liability was estimated using the following weighted-average assumptions, as determined in accordance with the terms of the warrant agreements, at March 31, 2015 and December 31, 2014:
		March 31,			December 31,
		2015			2014
	Risk-free interest rate		0.5	%		0.9	%
	Remaining term (years)		2.1			2.4
	Expected dividends		0	%		0	%
	Volatility		100	%		101.2	%
	The expected dividend yield was set at zero because the Company has never paid cash dividends and has no present intention to pay cash dividends. Expected volatility was based on the historical volatility of the Company’s common stock and was equal to the greater of 100% or the 30-day volatility rate. The risk-free interest rates were taken from the Daily Federal Yield Curve Rates as published by the Federal Reserve and represent the yields on actively traded U.S. Treasury securities for a term equal to the remaining term of the warrants.
	The following table provides a summary of changes in the fair value of the Company’s warrant liability, its only Level 3 financial liability, for the three months ended March 31, 2015 (in thousands):
	Balance at December 31, 2014	$	1,191
	Net decrease in fair value of warrant liability on remeasurement		(232	)
	Balance at March 31, 2015	$	959
	The net decrease in the estimated fair value of the warrant liability was recognized as income under “Change in fair value of warrant liability” in the Condensed Consolidated Statements of Operations.
	The warrant liability’s exposure to market risk will vary over time depending on interest rates and the Company’s stock price. Although the table above reflects the current estimated fair value of the warrant liability, it does not reflect the gains or losses associated with market exposures, which will depend on actual market conditions during the remaining life of the warrants.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers. The FASB and the International Accounting Standards Board (“IASB”) initiated a joint project to clarify the principles for recognizing revenue and developed a common revenue recognition standard for U.S. generally accepted accounting principles (“GAAP’) and International Financial Reporting Standards (“IFRS”). Under the guidance, an entity should recognize revenue when the entity satisfies a performance obligation within a contract at a determined transaction price. This update is effective for interim and annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. The Company does not expect that the adoption of this standard will materially impact the Company’s consolidated statement of financial position or results of operations.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (“ASU 2014-15”), Presentation of Financial Statements – Going Concern. This standard includes guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern within one year after the financial statements are issued. If conditions or events raise substantial doubt, the entity must disclose the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, management’s evaluation of those conditions or events, and management’s plans to mitigate the conditions or events. This update is effective for interim and annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company does not expect that the adoption of this standard will materially impact the Company’s consolidated statement of financial position or results of operations.
	In April 2015, the FASB issued Accounting Standards Update No. 2015-03 (“ASU 2015-03”), Simplifying the Presentation of Debt Issuance Costs. This standard requires that debt issuance costs be presented in the balance sheet as a direct reduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The update is effective for annual and interim reporting periods beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. The new guidance will be applied on a retrospective basis. The Company does not expect that the adoption of this standard will materially impact the Company’s consolidated statement of financial position or results of operations.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Note 2. Stock-Based Compensation
	Equity Incentive Program
	In 2007, the Company’s stockholders approved the Company’s 2007 Performance Incentive Plan (the “2007 Plan”), which provides for grants of options and other equity-based awards to the Company’s employees, directors and consultants. Options granted under this plan, and its predecessor plan, expire 10 years after the date of grant and become exercisable at such times and under such conditions as determined by the Company’s Board of Directors (generally, with 25% vesting after one year and the balance vesting on a daily basis over the next three years of service). Upon termination of the optionee’s service, unvested options terminate and vested options generally expire three months thereafter, if not exercised. Only nonqualified stock options have been granted under these plans to date. On January 1 of each calendar year during the term of the 2007 Plan, the shares of common stock available for issuance under the 2007 Plan will be increased by the lesser of (i) 2% of the total outstanding shares of common stock on December 31 of the preceding calendar year and (ii) 3,000,000 shares. The Board of Directors of the Company delayed the effectiveness of the January 1, 2015 increase in the number of shares available for issuance under the 2007 Plan until the Company’s stockholders approved an increase in the authorized shares of common stock under the Company’s Certificate of Incorporation from 240,000,000 to 350,000,000. The share increase was approved by the Company’s stockholders on March 31, 2015 and effected on April 1, 2015. Therefore, on April 1, 2015, the shares of common stock available for issuance under the 2007 Plan increased by 2,639,020 shares.
	Stock-based Compensation
	The Company’s stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service period. All of the Company’s stock compensation is accounted for as an equity instrument.
	The effect of recording stock-based compensation for the three months ended March 31, 2015 and 2014 was as follows (in thousands):
		Three months ended
		March 31,
		2015			2014
	Stock-based compensation expense by type of award:
	Employee stock options	$	192		$	255
	Scientific Advisory Board stock options		(1	)		(3	)
	Total stock-based compensation expense	$	191		$	252
	Stock-based compensation included in expense line items in the Condensed Consolidated Statements of Operations for the three months ended March 31, 2015 and 2014 was as follows (in thousands):
		Three months ended
		March 31,
		2015			2014
	Research and development	$	92		$	104
	General and administrative		99			148
		$	191		$	252
	During the three months ended March 31, 2015 and 2014, the Company granted options to purchase 2,875,000 and 2,777,000 shares of common stock, respectively, with an estimated total grant date fair value of $415,000 and $555,000, respectively. Based on the Company’s historical experience of option pre-vesting cancellations and estimates of future forfeiture rates, the Company has assumed an annualized forfeiture rate of 10% for its options for all periods disclosed. Accordingly, for the quarters ended March 31, 2015 and 2014, the Company estimated that the stock-based compensation for the awards not expected to vest was $270,000 and $319,000, respectively.
	As of March 31, 2015, unrecorded deferred stock-based compensation balance related to stock options was $1.1 million and will be recognized over an estimated weighted-average amortization period of 2.7 years.
	Valuation assumptions
	The Company estimates the fair value of stock options using a Black-Scholes valuation model using the graded-vesting method with the following weighted-average assumptions:
		Three months ended March 31,
	Stock Options	2015			2014
	Risk-free interest rate		1.3	%		1.7	%
	Expected term (years)		5			5
	Expected dividends		0	%		0	%
	Volatility		88.8	%		88.2	%
	The expected dividend yield was set at zero because the Company has never paid cash dividends and has no present intention to pay cash dividends. Expected volatility was based on the historical volatility of the Company’s common stock and the expected moderation in future volatility over the period commensurate with the expected life of the options and other factors. The risk-free interest rates were taken from the Daily Federal Yield Curve Rates as of the grant dates as published by the Federal Reserve and represent the yields on actively traded U.S. Treasury securities for terms equal to the expected term of the options. The expected term calculation was based on the terms utilized by the Company’s peers, observed historical option exercise behavior and post-vesting forfeitures of options by the Company’s employees.
	The following is a summary of activity for the indicated periods:
		Number of			Weighted-Average			Weighted-Average		Aggregate
		shares			Exercise Price			Remaining Contractual		Intrinsic Value
								Term (Years)		(in thousands)
	Outstanding at December 31, 2014		20,744,641		$	0.37
	Granted		2,875,000			0.21
	Exercised		—			0
	Forfeited		(65,736	)		0.29
	Expired		(30,000	)		0.84
	Outstanding at March 31, 2015		23,523,905		$	0.35			6.97	$	0
	Options vested and expected to vest at March 31, 2015		22,653,283		$	0.35			6.87	$	0
	Options exercisable at March 31, 2015		15,897,659		$	0.39			5.98	$	0
	At March 31, 2015, the Company had 734,453 shares of common stock available for grant or issuance under its 2007 Plan. The weighted average grant date fair value of options granted during the three months ended March 31, 2015 and 2014 was $0.14 and $0.20 per share, respectively. No options were exercised during the three months ended March 31, 2015 and 2014.

Net_Loss_per_Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Loss per Share	Note 3. Net Loss per Share
	Basic net loss per share has been computed using the weighted-average number of common shares outstanding during the period. Dilutive net loss per share was computed using the sum of the weighted average number of common shares outstanding and the potential number of dilutive common shares outstanding during the period. Potential common shares consist of the shares issuable upon exercise of stock options and warrants. Potentially dilutive securities have been excluded from the computation of diluted net loss per share in 2015 and 2014 as their inclusion would be anti-dilutive. For the three months ended March 31, 2015 and 2014, respectively, 43,393,351 and 34,557,625 options and warrants were excluded from the calculation of diluted net loss per share because the effect was anti-dilutive.
	The following table sets forth the computation of basic and diluted net loss per share:
		Three months ended
		March 31,
	(in thousands, except per share data)	2015			2014
	Numerator:
	Net loss	$	(828	)	$	(4,679	)
	Denominator:
	Weighted-average shares outstanding		131,951			131,951
	Effect of dilutive securities:
	Stock options		—			—
	Weighted-average shares outstanding for diluted loss per share		131,951			131,951
	Net loss per share:
	Basic	$	(0.01	)	$	(0.04	)
	Diluted	$	(0.01	)	$	(0.04	)

Warrant_Liability

Warrant Liability	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Warrant Liability	Note 4. Warrant Liability
	In July 2011, the Company completed a private placement equity financing transaction in which it sold shares of its common stock and warrants to purchase shares of its common stock. The Company sold a total of 36,978,440 shares of common stock, at a price of $0.60 per share, and issued warrants to purchase up to 14,791,376 shares of common stock. The warrants are exercisable at $0.75 per share and expire five years from the date of issuance. The private placement resulted in $22.2 million in gross proceeds and approximately $20.4 million in net proceeds to the Company after deducting placement agent fees, legal, accounting and other costs associated with the transaction. The Company used the net proceeds of the transaction to fund clinical trials and for general corporate purposes, including working capital.
	In the fourth quarter of 2014, the Company completed private placement debt financing transactions for $5.2 million. In connection with the debt financings, the Company issued warrants to purchase up to 2,053,169 shares, 200,620 shares and 2,824,281 shares of common stock that are exercisable at $0.33, $0.31 and $0.26, respectively, per share and expire five years from the date of issuance. The Company had the option to sell additional notes in an aggregate principal amount of $2.6 million (see Note 7, “Subsequent Events” for further discussion). The Company incurred $0.5 million in placement agent and legal fees in the fourth quarter of 2014.
	As discussed in Note 1, the warrants issued in 2011 and 2014 included a provision that provides the warrant holders with an option to require the Company (or its successor) to purchase the warrants for cash in an amount equal to the Black-Scholes value in the event of a “Fundamental Transaction” (as defined in the warrant agreements). Accordingly, the fair value of the warrants at the issuance date was estimated using the Black-Scholes Model, as determined in accordance with the terms of the warrant agreements, and the Company recorded a warrant liability of $6.4 million in 2011 and $1.0 million in 2014 and remeasured the warrant liability to $1.0 million and $1.2 million at March 31, 2015 and December 31, 2014, respectively. The Company recorded a decrease to the warrant liability of approximately $0.2 and $0.6 million for the three months ended March 31, 2015 and 2014, respectively, which was recognized as income in the Company’s Condensed Consolidated Statement of Operations. Additional disclosures regarding the assumptions used in calculating the fair value of the warrant liability are included in Note 1.

Common_Stock_Warrants

Common Stock Warrants	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Common Stock Warrants	Note 5. Common Stock Warrants
	The following table shows outstanding warrants as of March 31, 2015, all of which were issued in the July 2011 private placement equity financing transaction and in the 2014 private placement debt financing transactions. All of the outstanding warrants have cashless exercise provisions in the event the registration statement registering the resale of the shares of common stock issuable upon exercise of the warrants is not effective or the prospectus forming a part of the registration statement is not current. All warrants are exercisable for common stock.
	Date Issued	Warrant Shares		Exercise Price		Expiration Date	Potential Proceeds if
							Exercised for Cash
	18-Jul-11		14,791,376	$	0.75	July 18, 2016	$	11,093,532
	9-Oct-14		2,053,169	$	0.33	October 9, 2019	$	677,546
	21-Nov-14		200,620	$	0.31	November 21, 2019	$	62,192
	10-Dec-14		2,824,281	$	0.26	10-Dec-19	$	734,313
	Total		19,869,446				$	12,567,583

Legal_Proceedings

Legal Proceedings	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Note 6. Legal Proceedings
	The Company is subject to various claims and legal actions during the ordinary course of its business.
	In April 2011, the Company received a Notice Letter that Sandoz, Inc. or Sandoz, filed an Abbreviated New Drug Application, or ANDA, with the FDA seeking marketing approval for a 1% azithromycin ophthalmic solution, or the Sandoz Product, prior to the expiration of the five U.S. patents listed in the Orange Book for AzaSite, which include four of our patents and one patent licensed to us by Pfizer. In the paragraph IV Certification accompanying the Sandoz ANDA filing, Sandoz alleges that the claims of the Orange Book listed patents are invalid, unenforceable and/or will not be infringed upon by the Sandoz Product. On May 26, 2011, the Company, Merck and Pfizer filed a patent infringement lawsuit against Sandoz and related entities. The plaintiff companies agreed that Merck would take the lead in prosecuting this lawsuit. Before the trial, the patents involved in the litigation were limited to the one Pfizer patent and three of our patents. On October 4, 2013, the United States District Court for the District of New Jersey entered a Final Judgment in favor of us and the other plaintiffs finding all the asserted claims of the patents in the litigation valid and infringed by Sandoz and related entities. The Court Order specified that the effective date of any FDA approval of a Sandoz ANDA for generic 1% azithromycin ophthalmic solution products would be no earlier than the expiration date of the patents in the litigation. On November 4, 2013, Sandoz filed an appeal of this decision to the United States Court of Appeals for the Federal Circuit. On November 15, 2013, Akorn acquired Inspire from Merck, and as such, acquired the rights to AzaSite in North America. Akorn took the lead in prosecuting this lawsuit. On April 9, 2015, the Court of Appeals for the Federal Circuit affirmed the decision of the district court holding that Sandoz failed to show that the asserted claims in the patents-in-suit would have been obvious to a person of ordinary skill in the art. At this point, Sandoz’s only recourse is to seek en banc review by the Federal Circuit of the initial decision and/or to seek review by the Supreme Court. The Company and the other plaintiffs intend to vigorously contest any Sandoz assertions that these patents should have been found not infringed, invalid or unenforceable.
	In May 2013, the Company received a Notice Letter that Mylan Pharmaceuticals, Inc. or Mylan, filed an ANDA with the FDA seeking marketing approval for a 1% azithromycin ophthalmic solution, or the Mylan Product, prior to the expiration of the U.S. patents listed in the Orange Book for AzaSite, which include three of our patents and one patent licensed to us by Pfizer. In the paragraph IV Certification accompanying the Mylan ANDA filing, Mylan alleges that the claims of the Orange Book listed patents are invalid, unenforceable and/or will not be infringed upon by the Mylan Product. On June 14, 2013, the Company, Merck and Pfizer filed a patent infringement lawsuit against Mylan and a related entity. On November 15, 2013, Akorn acquired Inspire from Merck, and as such, acquired the rights to AzaSite in North America. The plaintiff companies agreed that Akorn would take the lead in prosecuting this lawsuit. The filing of this lawsuit triggered an automatic stay, or bar, of the FDA’s approval of the ANDA for up to 30 months or until a final district court decision of the infringement lawsuit, whichever comes first. In February 2015, all of the parties involved in the lawsuit executed a Settlement Agreement including all of the patents in the lawsuit and submitted the same to the United States District Court for the District of New Jersey. On March 4, 2015, the district court issued an Order for Dismissal, without prejudice.
	On July 24, 2014, Karin Stiens filed a complaint against Bausch & Lomb, Dr. Lance Ferguson and the Company (Fayette (Kentucky) Circuit Court Civil Action No. 14-CI-2829) alleging that she suffered ophthalmological damage when Dr. Ferguson engaged in off-label use of Besivance® in a photorefractive keratectomy procedure as a prophylactic antibiotic. The plaintiff alleges that Bausch & Lomb and the Company negligently tested, marketed and distributed Besivance, and negligently informed medical providers and consumers about Besivance. The complaint contains no facts supporting these general allegations, no facts supporting the plaintiff’s claim of permanent injuries and no allegations asserting Kentucky jurisdiction over the Company. The plaintiff has not pleaded any specific amount in damages nor made any demand. The Company filed its answer on August 18, 2014. The Company is investigating the plaintiff’s allegations.
	There are currently no other claims or legal actions that would have a material adverse impact on our financial position, operations or potential performance.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 7. Subsequent Events
	In the fourth quarter of 2014, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain purchasers (the “Purchasers”). Pursuant to the Purchase Agreement, the Company agreed to sell 12% Senior Secured Notes (the “Notes”) with a total loan commitment of $7.8 million to the Purchasers and issue warrants to purchase shares of the Company’s common stock. As of March 31, 2015, the Company had sold $5.2 million in Notes and had the option to sell additional Notes to the Purchasers in an aggregate principal amount of $2.6 million until October 9, 2016. In accordance with the Purchase Agreement, on April 17, 2015, the Company sold and issued Notes to the Purchasers having an aggregate principal amount equal to $2.6 million and issued warrants to purchase an aggregate of 3,464,456 shares of the Company’s common stock at an exercise price of $0.18 per share. Accordingly, the amounts that the Company can borrow under the Purchase Agreement are currently fully drawn.
	Riverbank Capital Securities acted as the placement agent (the “Placement Agent”) for the offering of Notes and warrants pursuant to the Purchase Agreement and received $155,900, a 6% cash commission on the gross proceeds from the sale of the Notes and issuance of the warrants on April 17, 2015. Timothy McInerney, the Chairman of the Board of the Company and a member of the Company’s Board of Directors, is a principal of the Placement Agent and is a Purchaser in the offering of Notes and warrants under the same terms as the other Purchasers.
	The Company evaluated subsequent events through the date on which the financial statements were issued and determined that there were no other subsequent events that required adjustments or disclosures to the financial statements for the quarter ended March 31, 2015.

Significant_Accounting_Policie1

Significant Accounting Policies and Use of Estimates (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements include the accounts of InSite Vision Incorporated (“InSite” or the “Company”) and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in the preparation of the condensed consolidated financial statements.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial results and financial condition have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for any future period.
	The Company operates in one segment using one measure of profitability to manage its business. All of the Company’s long-lived assets are located in the United States. Revenues are primarily royalties from the North American license (the “Akorn License”) of AzaSite® to Akorn, Inc. (“Akorn”).
	In January 2015, the Company entered into a license agreement with Nicox S.A. (“Nicox”), a France-based publicly traded company, for the development and commercialization of AzaSite (1% azithromycin), AzaSite XtraTM (2% azithromycin) and BromSiteTM (0.075% bromfenac) in Europe, Middle East and Africa (105 total countries). Under the terms of the license, the Company received an upfront payment of $3.0 million and could potentially receive $13.75 million in milestone payments. The Company will also receive tiered, mid-single digit to double-digit royalties on the net sales of these three products.
	Under the license agreement, Nicox can request up to twelve full-time equivalent (“FTE”) employees from the Company to assist with presenting data to regulatory authorities in the European Union, obtaining European Union regulatory approvals and dealing with the approved product manufacturer in the United States. Nicox has agreed to reimburse the Company for the use of its employees. Should the twelve FTE employees be needed for a full year, the reimbursement to the Company would be approximately $3.6 million.
	A joint collaboration and development committee will oversee further product development of the licensed products for the European Union including AzaSite Xtra and any additional indications for BromSite. The Company has the right to utilize the jointly developed data for regulatory approval outside of the Nicox territory including in the United States. Each company will bear 50% of the development cost.
	Historically, the Company has incurred substantial cumulative losses and negative cash flows from operations. Clinical trials and costs to prepare a New Drug Application (“NDA”) for the Company’s product candidates with the U.S. Food and Drug Administration (“FDA”) are very expensive and difficult, in part because they are subject to rigorous regulatory requirements. As of March 31, 2015, the Company’s accumulated deficit was $176.1 million and its cash and cash equivalents were $1.1 million. Further, the Company anticipates that its cash and cash equivalents balance, anticipated cash flows from operations and the net proceeds from existing debt financing arrangements will only be adequate to fund its operations until approximately July 2015. Management is exploring strategic alternatives or the raising of additional financing. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects relating to the recoverability and classification of the recorded asset amounts or amounts and classification of liabilities that might result from the outcome of this uncertainty.
	These unaudited condensed consolidated financial statements and notes should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
Use of Estimates	Use of Estimates
	The preparation of financial statements requires the Company to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.
Warrant Liability	Warrant Liability
	The Company issued warrants to purchase shares of the Company’s common stock in connection with a private placement equity financing transaction in July 2011 and private placement debt financing transactions in the fourth quarter of 2014. The Company accounted for these warrants as a liability measured at fair value due to a provision included in the warrant agreements that provides the warrant holders with an option to require the Company (or its successor) to purchase their warrants for cash in the event of a “Fundamental Transaction” (as defined in the warrant agreements). The actual amount of cash required if the mandatory purchase option is exercised would be determined using the Black-Scholes Option Pricing Model (the “Black-Scholes Model”) as determined in accordance with the terms of the warrant agreements. The fair value of the warrant liability is estimated using the Black-Scholes Model, which requires inputs such as the remaining term of the warrants, share price volatility and risk-free interest rate. These assumptions are reviewed on a monthly basis and changes in the estimated fair value of the outstanding warrants are recognized each reporting period in the Condensed Consolidated Statements of Operations under “Change in fair value of warrant liability.”
Fair Value Measurements	Fair Value Measurements
	Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
	Level 1:	Quoted prices in active markets for identical assets or liabilities.
	Level 2:	Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3:	Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.
	The Company’s financial instruments consist mainly of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and debt obligations. Accounts receivable and accounts payable are reflected in the accompanying unaudited condensed consolidated financial statements at cost, which approximates fair value due to the short-term nature of these instruments. While the Company believes its valuation methodologies are appropriate and consistent with those of other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
	At March 31, 2015, less than $0.1 million of the Company’s cash and cash equivalents consisted of Level 1 U.S. Treasury-backed government securities or money market funds that are measured at fair value on a recurring basis.
	As discussed above, the fair value of the warrant liability, determined using Level 3 criteria, was initially recorded on the grant date and remeasured at March 31, 2015 and December 31, 2014 using the Black-Scholes Model, which requires inputs such as the remaining term of the warrants, share price volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. A significant increase (decrease) of any of the subjective variables would result in a correlated increase (decrease) in the warrant liability and an inverse effect on net income (loss).
	The fair value of the warrant liability was estimated using the following weighted-average assumptions, as determined in accordance with the terms of the warrant agreements, at March 31, 2015 and December 31, 2014:
		March 31,			December 31,
		2015			2014
	Risk-free interest rate		0.5	%		0.9	%
	Remaining term (years)		2.1			2.4
	Expected dividends		0	%		0	%
	Volatility		100	%		101.2	%
	The expected dividend yield was set at zero because the Company has never paid cash dividends and has no present intention to pay cash dividends. Expected volatility was based on the historical volatility of the Company’s common stock and was equal to the greater of 100% or the 30-day volatility rate. The risk-free interest rates were taken from the Daily Federal Yield Curve Rates as published by the Federal Reserve and represent the yields on actively traded U.S. Treasury securities for a term equal to the remaining term of the warrants.
	The following table provides a summary of changes in the fair value of the Company’s warrant liability, its only Level 3 financial liability, for the three months ended March 31, 2015 (in thousands):
	Balance at December 31, 2014	$	1,191
	Net decrease in fair value of warrant liability on remeasurement		(232	)
	Balance at March 31, 2015	$	959
	The net decrease in the estimated fair value of the warrant liability was recognized as income under “Change in fair value of warrant liability” in the Condensed Consolidated Statements of Operations.
	The warrant liability’s exposure to market risk will vary over time depending on interest rates and the Company’s stock price. Although the table above reflects the current estimated fair value of the warrant liability, it does not reflect the gains or losses associated with market exposures, which will depend on actual market conditions during the remaining life of the warrants.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (“ASU 2014-09”), Revenue from Contracts with Customers. The FASB and the International Accounting Standards Board (“IASB”) initiated a joint project to clarify the principles for recognizing revenue and developed a common revenue recognition standard for U.S. generally accepted accounting principles (“GAAP’) and International Financial Reporting Standards (“IFRS”). Under the guidance, an entity should recognize revenue when the entity satisfies a performance obligation within a contract at a determined transaction price. This update is effective for interim and annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. The Company does not expect that the adoption of this standard will materially impact the Company’s consolidated statement of financial position or results of operations.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15 (“ASU 2014-15”), Presentation of Financial Statements – Going Concern. This standard includes guidance about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern within one year after the financial statements are issued. If conditions or events raise substantial doubt, the entity must disclose the conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern, management’s evaluation of those conditions or events, and management’s plans to mitigate the conditions or events. This update is effective for interim and annual reporting periods beginning after December 15, 2016. Early adoption is permitted. The Company does not expect that the adoption of this standard will materially impact the Company’s consolidated statement of financial position or results of operations.
	In April 2015, the FASB issued Accounting Standards Update No. 2015-03 (“ASU 2015-03”), Simplifying the Presentation of Debt Issuance Costs. This standard requires that debt issuance costs be presented in the balance sheet as a direct reduction from the carrying value of the associated debt liability, consistent with the presentation of a debt discount. The update is effective for annual and interim reporting periods beginning after December 15, 2015. Early adoption is permitted for financial statements that have not been previously issued. The new guidance will be applied on a retrospective basis. The Company does not expect that the adoption of this standard will materially impact the Company’s consolidated statement of financial position or results of operations.
Net Loss per Share	Basic net loss per share has been computed using the weighted-average number of common shares outstanding during the period. Dilutive net loss per share was computed using the sum of the weighted average number of common shares outstanding and the potential number of dilutive common shares outstanding during the period. Potential common shares consist of the shares issuable upon exercise of stock options and warrants. Potentially dilutive securities have been excluded from the computation of diluted net loss per share in 2015 and 2014 as their inclusion would be anti-dilutive. For the three months ended March 31, 2015 and 2014, respectively, 43,393,351 and 34,557,625 options and warrants were excluded from the calculation of diluted net loss per share because the effect was anti-dilutive.

Significant_Accounting_Policie2

Significant Accounting Policies and Use of Estimates (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Estimated Fair Value of Warrant Liability	The fair value of the warrant liability was estimated using the following weighted-average assumptions, as determined in accordance with the terms of the warrant agreements, at March 31, 2015 and December 31, 2014:
		March 31,			December 31,
		2015			2014
	Risk-free interest rate		0.5	%		0.9	%
	Remaining term (years)		2.1			2.4
	Expected dividends		0	%		0	%
	Volatility		100	%		101.2	%
Changes in Fair Value of Warrant Liability of Level Three Financial Liability	The following table provides a summary of changes in the fair value of the Company’s warrant liability, its only Level 3 financial liability, for the three months ended March 31, 2015 (in thousands):
	Balance at December 31, 2014	$	1,191
	Net decrease in fair value of warrant liability on remeasurement		(232	)
	Balance at March 31, 2015	$	959

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	The effect of recording stock-based compensation for the three months ended March 31, 2015 and 2014 was as follows (in thousands):
		Three months ended
		March 31,
		2015			2014
	Stock-based compensation expense by type of award:
	Employee stock options	$	192		$	255
	Scientific Advisory Board stock options		(1	)		(3	)
	Total stock-based compensation expense	$	191		$	252
Stock-Based Compensation Expenses	Stock-based compensation included in expense line items in the Condensed Consolidated Statements of Operations for the three months ended March 31, 2015 and 2014 was as follows (in thousands):
		Three months ended
		March 31,
		2015			2014
	Research and development	$	92		$	104
	General and administrative		99			148
		$	191		$	252
Weighted-Average Fair Value Assumptions of Stock Options	The Company estimates the fair value of stock options using a Black-Scholes valuation model using the graded-vesting method with the following weighted-average assumptions:
		Three months ended March 31,
	Stock Options	2015			2014
	Risk-free interest rate		1.3	%		1.7	%
	Expected term (years)		5			5
	Expected dividends		0	%		0	%
	Volatility		88.8	%		88.2	%
Summary of Stock Option Activity	The following is a summary of activity for the indicated periods:
		Number of			Weighted-Average			Weighted-Average		Aggregate
		shares			Exercise Price			Remaining Contractual		Intrinsic Value
								Term (Years)		(in thousands)
	Outstanding at December 31, 2014		20,744,641		$	0.37
	Granted		2,875,000			0.21
	Exercised		—			0
	Forfeited		(65,736	)		0.29
	Expired		(30,000	)		0.84
	Outstanding at March 31, 2015		23,523,905		$	0.35			6.97	$	0
	Options vested and expected to vest at March 31, 2015		22,653,283		$	0.35			6.87	$	0
	Options exercisable at March 31, 2015		15,897,659		$	0.39			5.98	$	0

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Loss per Share	The following table sets forth the computation of basic and diluted net loss per share:
		Three months ended
		March 31,
	(in thousands, except per share data)	2015			2014
	Numerator:
	Net loss	$	(828	)	$	(4,679	)
	Denominator:
	Weighted-average shares outstanding		131,951			131,951
	Effect of dilutive securities:
	Stock options		—			—
	Weighted-average shares outstanding for diluted loss per share		131,951			131,951
	Net loss per share:
	Basic	$	(0.01	)	$	(0.04	)
	Diluted	$	(0.01	)	$	(0.04	)

Common_Stock_Warrants_Tables

Common Stock Warrants (Tables)	3 Months Ended
	Mar. 31, 2015
Text Block [Abstract]
Outstanding Common Stock Warrants	The following table shows outstanding warrants as of March 31, 2015, all of which were issued in the July 2011 private placement equity financing transaction and in the 2014 private placement debt financing transactions. All of the outstanding warrants have cashless exercise provisions in the event the registration statement registering the resale of the shares of common stock issuable upon exercise of the warrants is not effective or the prospectus forming a part of the registration statement is not current. All warrants are exercisable for common stock.
	Date Issued	Warrant Shares		Exercise Price		Expiration Date	Potential Proceeds if
							Exercised for Cash
	18-Jul-11		14,791,376	$	0.75	July 18, 2016	$	11,093,532
	9-Oct-14		2,053,169	$	0.33	October 9, 2019	$	677,546
	21-Nov-14		200,620	$	0.31	November 21, 2019	$	62,192
	10-Dec-14		2,824,281	$	0.26	10-Dec-19	$	734,313
	Total		19,869,446				$	12,567,583

Significant_Accounting_Policie3

Significant Accounting Policies and Use of Estimates - Additional Information (Detail) (USD $)	3 Months Ended	0 Months Ended	1 Months Ended	12 Months Ended
	Mar. 31, 2015	Jan. 31, 2015	Jan. 31, 2015	Dec. 31, 2014		Mar. 31, 2014	Dec. 31, 2013
	Segment
Schedule Of Description Of Business Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of operating segment	1
Accumulated deficit	($176,090,000)			-175,262,000	[1]
Cash and cash equivalents	1,050,000			1,656,000	[1]	4,353,000	3,251,000
Nicox [Member]
Schedule Of Description Of Business Basis Of Presentation And Significant Accounting Policies [Line Items]
License agreement terms	In January 2015, the Company entered into a license agreement with Nicox S.A. ("Nicox"), a France-based publicly traded company, for the development and commercialization of AzaSite (1% azithromycin), AzaSite XtraTM (2% azithromycin) and BromSiteTM(0.075% bromfenac) in Europe, Middle East and Africa (105 total countries).
License agreement date	31-Jan-15
Upfront payment received			3,000,000
Potential future upfront license payments to be received			13,750,000
Royalty description	Mid-single digit to double-digit royalties on the net sales.
Employee product assistance service reimbursement		3,600,000
Development cost percentage		50.00%
Level 1 [Member] | Fair Value on Recurring Basis [Member] | U.S. Treasury-backed Money Market Funds [Member] | Maximum [Member]
Schedule Of Description Of Business Basis Of Presentation And Significant Accounting Policies [Line Items]
Cash and cash equivalents at fair value	100,000
Level 3 [Member] | Fair Value on Recurring Basis [Member] | Warrant [Member]
Schedule Of Description Of Business Basis Of Presentation And Significant Accounting Policies [Line Items]
Expected dividend yield on warrant liabilities	0.00%			0.00%
Cash dividends	$0
Fair value of liabilities, volatility rate description	Expected volatility was based on the historical volatility of the Company's common stock and was equal to the greater of 100% or the 30-day volatility rate.
Fair value of liabilities, expected volatility rate	100.00%			101.20%
Fair value of liabilities, duration of volatility rate	30 days
[1]	Derived from the Company's audited consolidated financial statements as of December 31, 2014.

Significant_Accounting_Policie4

Significant Accounting Policies and Use of Estimates - Estimated Fair Value of Warrant Liability (Detail) (Warrant [Member], Level 3 [Member], Fair Value on Recurring Basis [Member])	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Warrant [Member] | Level 3 [Member] | Fair Value on Recurring Basis [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	0.50%	0.90%
Remaining term (years)	2 years 1 month 6 days	2 years 4 months 24 days
Expected dividends	0.00%	0.00%
Volatility	100.00%	101.20%

Significant_Accounting_Policie5

Significant Accounting Policies and Use of Estimates - Changes in Fair Value of Warrant Liability of Level Three Financial Liability (Detail) (Warrant [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at beginning of period	$1,191
Net decrease in fair value of warrant liability on remeasurement	-232	600
Balance at end of period	$959

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014		Apr. 01, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted, Performance Incentive Plan expiration period	10 years
Options vested, Performance Incentive Plan one year in percentage	25.00%
Balance options vested in daily basis	3 years
Unvested options terminate and vested options generally expire	3 months
Common stock available for issuance and increased percentage of the total	2.00%
Common stock shares available for issuance outstanding	3,000,000
Common stock, shares authorized	240,000,000		240,000,000	[1]
Increase in the number of shares of common stock available for issuance	2,639,020
Common stock, shares granted options to purchase	2,875,000	2,777,000
Common stock, shares estimated total grant date fair value	$415,000	$555,000
Common stock, shares annualized forfeiture rate	10.00%
Stock-based compensation not expected to vest	270,000	319,000
Unrecorded deferred stock-based compensation	$1,100,000
Recognized estimated weighted-average amortization period	2 years 8 months 12 days
Expected dividend yield	0.00%	0.00%
Common stock, shares available for grant or issuance under 2007 Plan	734,453
Weighted average fair value options granted	$0.14	$0.20
Options exercised	0	0
Subsequent Events [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized					350,000,000
[1]	Derived from the Company's audited consolidated financial statements as of December 31, 2014.

StockBased_Compensation_StockB

Stock-Based Compensation - Stock-Based Compensation (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$191	$252
Employee Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	192	255
Non-employee Stock Options Scientific Advisory Board Stock Options [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	($1)	($3)

StockBased_Compensation_StockB1

Stock-Based Compensation - Stock-Based Compensation Expenses (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$191	$252
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	92	104
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$99	$148

StockBased_Compensation_Weight

Stock-Based Compensation - Weighted-Average Fair Value Assumptions of Stock Options (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Risk-free interest rate	1.30%	1.70%
Expected term (years)	5 years	5 years
Expected dividends	0.00%	0.00%
Volatility	88.80%	88.20%

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Stock Option Activity (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Number of shares
Outstanding at beginning balance	20,744,641
Granted	2,875,000	2,777,000
Exercised	0	0
Forfeited	-65,736
Expired	-30,000
Outstanding at ending balance	23,523,905
Options vested and expected to vest at ending balance	22,653,283
Options exercisable at ending balance	15,897,659
Weighted-Average Exercise Price
Outstanding at beginning balance	$0.37
Granted	$0.21
Exercised	$0
Forfeited	$0.29
Expired	$0.84
Outstanding at ending balance	$0.35
Options vested and expected to vest at ending balance	$0.35
Options exercisable at ending balance	$0.39
Weighted-Average Remaining Contractual Term (Years)
Outstanding at ending balance	6 years 11 months 19 days
Options vested and expected to vest at ending balance	6 years 10 months 13 days
Options exercisable at ending balance	5 years 11 months 23 days
Aggregate Intrinsic Value
Outstanding at ending balance	$0

Net_Loss_per_Share_Additional_

Net Loss per Share - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Options and warrants excluded from calculation of diluted net income per share	43,393,351	34,557,625

Net_Loss_per_Share_Computation

Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Numerator:
Net loss	($828)	($4,679)
Denominator:
Weighted-average shares outstanding	131,951	131,951
Effect of dilutive securities:
Stock options	0	0
Weighted-average shares outstanding for diluted loss per share	131,951	131,951
Net loss per share:
Basic	($0.01)	($0.04)
Diluted	($0.01)	($0.04)

Warrant_Liability_Additional_I

Warrant Liability - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		0 Months Ended			3 Months Ended
	Jul. 31, 2011	Mar. 31, 2015	Dec. 31, 2014	Dec. 10, 2014	Nov. 21, 2014	Oct. 09, 2014	Mar. 31, 2014	Dec. 31, 2011
Class of Warrant or Right [Line Items]
Gross proceeds from private placement	$22,200,000
Net proceeds from private placement	20,400,000
Proceeds from issuance of notes		2,600,000	5,200,000
Placement agent and legal fees			500,000
Common Stock [Member]
Class of Warrant or Right [Line Items]
Number of common stock sold	36,978,440
Selling price per share	$0.60
Number of warrants issued to purchase common stock	14,791,376	19,869,446		2,824,281	200,620	2,053,169
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants exercise price	$0.75			$0.26	$0.31	$0.33
Expiration period of warrants	5 years			5 years	5 years	5 years
Warrant liability		959,000	1,191,000
Decrease in warrant liability		-232,000					600,000
Warrant [Member] | Previously Reported [Member]
Class of Warrant or Right [Line Items]
Warrant liability			$1,000,000					$6,400,000

Common_Stock_Warrants_Outstand

Common Stock Warrants - Outstanding Common Stock Warrants (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 10, 2014	Nov. 21, 2014	Oct. 09, 2014	Jul. 31, 2011
Warrant [Member]
Class of Warrant or Right [Line Items]
Exercise Price		$0.26	$0.31	$0.33	$0.75
Potential Proceeds if Exercised for Cash	$12,567,583
Warrant [Member] | Warrants Issued On July 18, 2011 [Member]
Class of Warrant or Right [Line Items]
Date Issued	18-Jul-11
Exercise Price	$0.75
Expiration Date	18-Jul-16
Potential Proceeds if Exercised for Cash	11,093,532
Warrant [Member] | Warrants Issued On October 9, 2014 [Member]
Class of Warrant or Right [Line Items]
Date Issued	9-Oct-14
Exercise Price	$0.33
Expiration Date	9-Oct-19
Potential Proceeds if Exercised for Cash	677,546
Warrant [Member] | Warrants Issued On November 21, 2014 [Member]
Class of Warrant or Right [Line Items]
Date Issued	21-Nov-14
Exercise Price	$0.31
Expiration Date	21-Nov-19
Potential Proceeds if Exercised for Cash	62,192
Warrant [Member] | Warrants Issued On December 10, 2014 [Member]
Class of Warrant or Right [Line Items]
Date Issued	10-Dec-14
Exercise Price	$0.26
Expiration Date	10-Dec-19
Potential Proceeds if Exercised for Cash	$734,313
Common Stock [Member]
Class of Warrant or Right [Line Items]
Warrant Shares	19,869,446	2,824,281	200,620	2,053,169	14,791,376
Common Stock [Member] | Warrants Issued On July 18, 2011 [Member]
Class of Warrant or Right [Line Items]
Warrant Shares	14,791,376
Common Stock [Member] | Warrants Issued On October 9, 2014 [Member]
Class of Warrant or Right [Line Items]
Warrant Shares	2,053,169
Common Stock [Member] | Warrants Issued On November 21, 2014 [Member]
Class of Warrant or Right [Line Items]
Warrant Shares	200,620
Common Stock [Member] | Warrants Issued On December 10, 2014 [Member]
Class of Warrant or Right [Line Items]
Warrant Shares	2,824,281

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail)	0 Months Ended
	Jun. 14, 2013	Apr. 30, 2011	31-May-13	26-May-11
		Patent	Patent	Patent
Legal Proceedings [Line Items]
Number of patents infringed		5
Maximum [Member]
Legal Proceedings [Line Items]
Period for filing of lawsuit	30 months
Company [Member]
Legal Proceedings [Line Items]
Number of patents infringed		4	3	3
Pfizer Inc [Member]
Legal Proceedings [Line Items]
Number of patents infringed		1	1	1

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Apr. 17, 2015
Subsequent Event [Line Items]
Proceeds from issuance of notes	$2,600,000	$5,200,000
Senior Secured Notes [Member]
Subsequent Event [Line Items]
Additional warrants connection with notes, expiration date	9-Oct-16
Securities Purchase Agreement [Member] | Senior Secured Notes [Member]
Subsequent Event [Line Items]
Debt instrument interest rate		12.00%
Senior secured notes	5,200,000
Proceeds from issuance of notes	2,600,000
Securities Purchase Agreement [Member] | Senior Secured Notes [Member] | Loan Purchase Commitments [Member]
Subsequent Event [Line Items]
Debt Instrument Aggregate Principal amount		7,800,000
Subsequent Events [Member] | Securities Purchase Agreement [Member] | Senior Secured Notes [Member]
Subsequent Event [Line Items]
Proceeds from issuance of notes			2,600,000
Number of warrants issued to purchase common stock			3,464,456
Warrants exercise price			$0.18
Subsequent Events [Member] | Securities Purchase Agreement [Member] | Maximum [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Payments for offering of notes			$155,900
Percentage of commission received upon issue of warrants			6.00%